Literature DB >> 7547930

Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin.

J Rim1, D D Oprian.   

Abstract

Mutation of Gly90, Glu113, Ala292, and Lys296 in the visual pigment rhodopsin constitutively activates the protein for activation of the G protein transducin. Three of these mutations have been shown to cause two different human diseases. Mutation of Gly90 and Ala292 results in complete night blindness, and mutation of Lys296 results in the degenerative disease retinitis pigmentosa. We show here that the mutants not only constitutively activate transducin but are also constitutively activated for phosphorylation by rhodopsin kinase. In addition, the phosphorylated mutants are shown to bind tightly to the inhibitory protein arrestin in a reaction that quenches the activity toward transducin. Thus the same mutations that result in constitutive activation of transducin also result in constitutive phosphorylation by rhodopsin kinase and binding of arrestin to inhibit the activity. This implies that the same conformational change may be responsible for activation of transducin and rhodopsin kinase. It also suggests that degeneration of photoreceptor cells in retinitis pigmentosa results indirectly from the activated state of the receptor, perhaps as a consequence of phosphorylation and persistent binding of arrestin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547930     DOI: 10.1021/bi00037a035

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

1.  Structure and function in rhodopsin: kinetic studies of retinal binding to purified opsin mutants in defined phospholipid-detergent mixtures serve as probes of the retinal binding pocket.

Authors:  P J Reeves; J Hwa; H G Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Arrestin can act as a regulator of rhodopsin photochemistry.

Authors:  Martha E Sommer; David L Farrens
Journal:  Vision Res       Date:  2006-10-27       Impact factor: 1.886

Review 3.  The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2006-02-03       Impact factor: 12.310

Review 4.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

Review 5.  Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors.

Authors:  P J Pauwels; T Wurch
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

Review 6.  Mechanisms of cell death in the inherited retinal degenerations.

Authors:  G H Travis
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Synthesis and characterization of a novel retinylamine analog inhibitor of constitutively active rhodopsin mutants found in patients with autosomal dominant retinitis pigmentosa.

Authors:  T Yang; B B Snider; D D Oprian
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Engineering visual arrestin-1 with special functional characteristics.

Authors:  Sergey A Vishnivetskiy; Qiuyan Chen; Maria C Palazzo; Evan K Brooks; Christian Altenbach; Tina M Iverson; Wayne L Hubbell; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 9.  Constitutively active rhodopsin and retinal disease.

Authors:  Paul Shin-Hyun Park
Journal:  Adv Pharmacol       Date:  2014

10.  Effect of g protein-coupled receptor kinase 1 (Grk1) overexpression on rod photoreceptor cell viability.

Authors:  Tiffany Whitcomb; Keisuke Sakurai; Bruce M Brown; Joyce E Young; Lowell Sheflin; Cynthia Dlugos; Cheryl M Craft; Vladimir J Kefalov; Shahrokh C Khani
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.